Q2 2018 Investor Conference Call

Wednesday, September 5, 2018
Start at approx. 2:00 p.m. CEST (12:00 noon UTC)


Investor News September 05, 2018

Second quarter of 2018

Bayer completes biggest acquisition in its history

Monsanto business included on prorated basis from June 7 / Group sales advance by 8.5 percent (Fx & portfolio adj.) to 9.481 billion euros / EBITDA before special items increases by 3.9 percent to 2.335 billion euros despite unfavorable currency effects / Pharmaceuticals registers hvestors andigher sales (Fx & portfolio adj.) but lower earnings - substantial increase in R&D investment / Consumer Health business weak again / Crop Science achieves strong increase in sales and earnings after weak prior-year quarter / Animal Health improves sales (Fx & portfolio adj.) and earnings / Net income amounts to 799 million euros / Core earnings per share up by 1.3 percent at 1.54 euros / Group outlook for 2018 confirmed, with adjustments to reflect acquisition 


 

Baumann_125px_201604_349b74.jpg

Werner Baumann
CEO of Bayer AG

Audio recording of the investor conference call

 

Audio file

You can also play the audio recording on your mobile device.

 

Nickl_125px_20180725_55.png

Wolfgang Nickl
CFO of Bayer AG

Presentation charts

Interim Report Second Quarter 2018

Q2 2018 Analyst and Investor Briefing

Transcript

Q2 2018 All in One Package for Investors and Analysts 

Supplemental financial information with regard to Bayer including Monsanto ahead of Q2 2018 results, 
August 08, 2018